within Pharmacolibrary.Drugs.ATC.S;

model S01EE05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 0.005 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01EE05</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tafluprost is a prostaglandin analog used in the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is an ophthalmic solution that lowers intraocular pressure by increasing the outflow of aqueous humor. Tafluprost is currently approved and in use as an eye drop.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data after ophthalmic (eye drop) administration in healthy adult subjects; measurement performed on tafluprost acid (active metabolite) due to rapid hydrolysis of parent drug.</p><h4>References</h4><ol><li><p>Uusitalo, H, et al., &amp; Ropo, A (2008). Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. <i>Acta ophthalmologica. Supplement</i> 242 7–13. DOI:<a href=&quot;https://doi.org/10.1111/j.1755-3768.2008.01380.x&quot;>10.1111/j.1755-3768.2008.01380.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18752509/&quot;>https://pubmed.ncbi.nlm.nih.gov/18752509</a></p></li><li><p>Akaishi, T, et al., &amp; Kawazu, K (2015). Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 31(9) 518–524. DOI:<a href=&quot;https://doi.org/10.1089/jop.2015.0031&quot;>10.1089/jop.2015.0031</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26325164/&quot;>https://pubmed.ncbi.nlm.nih.gov/26325164</a></p></li><li><p>Fukano, Y, et al., &amp; Pellinen, P (2011). Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 27(3) 251–259. DOI:<a href=&quot;https://doi.org/10.1089/jop.2010.0178&quot;>10.1089/jop.2010.0178</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21491995/&quot;>https://pubmed.ncbi.nlm.nih.gov/21491995</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01EE05;
